Progyny Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on Progyny, Maintains $37 Price Target
Truist Financial Maintains Progyny(PGNY.US) With Buy Rating
Progyny Analyst Ratings
J.P. Morgan Maintains Progyny(PGNY.US) With Buy Rating, Announces Target Price $31
Analysts Offer Insights on Healthcare Companies: Sanofi (OtherSNYNF), Progyny (PGNY) and Health Catalyst (HCAT)
A Quick Look at Today's Ratings for Progyny(PGNY.US), With a Forecast Between $25 to $31
A Quick Look at Today's Ratings for Progyny(PGNY.US), With a Forecast Between $24 to $31
Progyny: Growth Potential Acknowledged Amid Execution Concerns – Hold Rating Maintained
Progyny (PGNY) Gets a Buy From Barclays
Progyny's Growth Trajectory and Market Differentiation Affirm Buy Rating
Progyny Analyst Ratings
Progyny Price Target Cut to $37.00/Share From $48.00 by Cantor Fitzgerald
Cantor Fitzgerald Maintains Overweight on Progyny, Lowers Price Target to $37
Truist Financial Reaffirms Their Buy Rating on Progyny (PGNY)
Canaccord Genuity Downgrades Progyny to Hold From Buy, Cuts Price Target to $24 From $37
Progyny Hold Rating: Adjusted Price Target and Concerns Over Uncertain Growth Trajectory
Progyny Analyst Ratings
Barclays Maintains Progyny(PGNY.US) With Buy Rating, Maintains Target Price $30
JMP Securities Maintains Progyny(PGNY.US) With Buy Rating, Cuts Target Price to $31